0.00
price down icon100.00%   -31.23
after-market  After Hours:  31.24  31.24   +
loading
Immunogen, Inc. stock is currently priced at $0.00, with a 24-hour trading volume of 0. It has seen a -100.00% decreased in the last 24 hours and a -100.00% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $31.23 pivot point. If it approaches the $31.19 support level, significant changes may occur.
Previous Close:
$31.23
Open:
$0
24h Volume:
0
Market Cap:
$8.72B
Revenue:
$287.61M
Net Income/Loss:
$-73.52M
P/E Ratio:
0.00
EPS:
-0.31
Net Cash Flow:
$-199.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1D Range:
Value
$0.00
$0.00
52W Range:
Value
$0.00
$31.25

Immunogen, Inc. Stock (IMGN) Company Profile

Name
Name
Immunogen, Inc.
Name
Phone
781-895-0600
Name
Address
830 Winter Street, Waltham, MA
Name
Employee
293
Name
Twitter
@immunogeninc
Name
Next Earnings Date
2024-02-28
Name
Latest SEC Filings
Name
IMGN's Discussions on Twitter

Immunogen, Inc. Stock (IMGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-01-23 Downgrade Guggenheim Buy → Neutral
Nov-20-23 Initiated Goldman Neutral
Nov-09-23 Initiated Deutsche Bank Buy
Oct-06-23 Initiated Oppenheimer Perform
May-03-23 Upgrade Piper Sandler Neutral → Overweight
Nov-21-22 Initiated Truist Buy
Sep-09-22 Initiated Barclays Overweight
Mar-21-22 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-11-22 Initiated BMO Capital Markets Outperform
Dec-01-21 Upgrade Jefferies Hold → Buy
Oct-26-20 Resumed H.C. Wainwright Buy
Oct-02-20 Upgrade Guggenheim Neutral → Buy
Sep-29-20 Resumed JP Morgan Neutral
Dec-17-19 Reiterated H.C. Wainwright Buy
Aug-13-19 Reiterated H.C. Wainwright Buy
May-15-19 Downgrade Guggenheim Buy → Neutral
May-06-19 Upgrade Cowen Market Perform → Outperform
May-06-19 Upgrade H.C. Wainwright Neutral → Buy
Mar-19-19 Downgrade JP Morgan Neutral → Underweight
Mar-05-19 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19 Downgrade H.C. Wainwright Buy → Neutral
Mar-04-19 Downgrade SVB Leerink Outperform → Mkt Perform
Mar-01-19 Downgrade Jefferies Buy → Hold
Mar-01-19 Downgrade Piper Jaffray Overweight → Neutral
Sep-07-18 Initiated Piper Jaffray Overweight
Feb-08-18 Resumed RBC Capital Mkts Outperform
Jan-31-18 Initiated H.C. Wainwright Buy
Jul-06-17 Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-19-17 Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16 Downgrade RBC Capital Mkts Outperform → Sector Perform
View All

Immunogen, Inc. Stock (IMGN) Financials Data

Immunogen, Inc. (IMGN) Revenue 2024

IMGN reported a revenue (TTM) of $287.61 million for the quarter ending September 30, 2023, a +200.83% rise year-over-year.
loading

Immunogen, Inc. (IMGN) Net Income 2024

IMGN net income (TTM) was -$73.52 million for the quarter ending September 30, 2023, a +63.44% increase year-over-year.
loading

Immunogen, Inc. (IMGN) Cash Flow 2024

IMGN recorded a free cash flow (TTM) of -$199.78 million for the quarter ending September 30, 2023, a +7.92% increase year-over-year.
loading

Immunogen, Inc. (IMGN) Earnings per Share 2024

IMGN earnings per share (TTM) was -$0.31 for the quarter ending September 30, 2023, a +62.20% growth year-over-year.
loading
ImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
$83.78
price down icon 1.10%
$156.11
price up icon 0.37%
$26.03
price up icon 0.58%
$84.64
price down icon 1.44%
$165.70
price up icon 5.27%
$394.47
price up icon 1.70%
Cap:     |  Volume (24h):